This study evaluated the effects of flavonoid-rich fraction from Bauhinia forficata leaves (FRF-BF), against intestinal toxicity induced by irinotecan. The leaves of this plant are used like tea in Brazilian folk medicine, and it is rich in flavonoids, mainly kaempferitrin.
This study evaluated the effects of flavonoid-rich fraction from Bauhinia forficata leaves (FRF-BF), against intestinal toxicity induced by irinotecan. The leaves of this plant are used like tea in Brazilian folk medicine, and it is rich in flavonoids, mainly kaempferitrin.
First, the chemopreventive effects of FRF-BF and kaempferitrin were evaluated in intestinal cells (IEC-6 cells) exposed to irinotecan. Next, the effects were evaluated against irinotecan-induced mucositis in mice. Lastly, melanoma was induced in C57BL/6 mice to evaluate FRF-BF interference on irinotecan antitumor activity. The results showed that FRF-BF and kaempferitrin exert no cytotoxic effects in IEC-6 cells and confirmed that pretreatment with FRF-BF and kaempferitrin displays chemoprotective effects against cytotoxicity induced by irinotecan. Interestingly, the FRF-BF (100 mg/kg, p.o) reduced the intestinal motility in mice and attenuated parameters linked to irinotecaninduced intestinal mucositis, including diarrhea, histological damage, depletion of duodenal GSH, amount of TNF-α, and MPO activity in the small intestine. Also, FRF-BF does not interfere in the antitumor activity of irinotecan and exerted antitumoral activity in murine melanoma. In conclusion, FRF-BF (100 mg/kg, p.o) presents promising pharmacological potential to prevent and attenuate the severity of intestinal mucositis during chemotherapy treatment, related to the presence of kaempferitrin. The cancer treatment includes strategies as chemotherapy, radiotherapy, surgery, or combined therapy, if necessary (Saletti, Sanna, Gabutti, & Ghielmini, 2018) . Lamentably, the side effects of these treatments are intense and occur in majority of patients (Song, Baik, Hong, & Sung, 2016) . Among chemotherapy side effects, alimentary mucositis represents a crucial problem in clinical oncology practice.
Alimentary mucositis is characterized by ulcerative lesions in the mucosa of the gastrointestinal tract, which in turn is associated with several symptoms, such as abdominal pain, anorexia, diarrhea, vomiting, and nausea Reinke et al., 2015; Santos-Filho et al., 2016) . Of this mode, this condition impacts negatively the life quality of patients submitted to the chemotherapy or radiotherapy treatment. Besides, this toxic side effect occurs in over 40% of cancer patients, leading to the interruption of the oncology treatment, compromising overall survival (Reinke et al., 2015; .
Irinotecan is a topoisomerase I inhibitor, used specially to treat colorectal cancer (U.S. National Library of Medicine, n.d.) . Despite their effectiveness as antineoplasic medicine, the deleterious effects of irinotecan at the nontumoral intestinal mucosa, mainly the duodenum, has been verified, and findings forcefully indicate that this chemotherapy causes tight junction defects on enterocytes, leading to mucosal barrier dysfunction and the occurrence of intestinal mucositis .
Although intestinal mucositis has been studied for over 30 years, there is still no clinically successful pharmacological therapy intervention to prevent or treat this condition . Some herbal products with anti-inflammatory and antioxidant properties have been recently studied as promising treatments of intestinal mucositis, such as acteoside (Reinke et al., 2015) , Curcuma longa L. , Bidens pilosa L. , wheat bran arabinoxylan supplementation (SONG et al., 2016) , Colotropis procera (de Alencar et al., 2017) , silymarin (Elyasi, Hosseini, Niazi Moghadam, Aledavood, & Karimi, 2016) , and the herbal preparation Bu-Zhong-Yi-Qi (Gou, Gu, Xiong, & Wang, 2016) . In agreements, the management of chemotherapy-induced nausea and vomiting has been achieved using traditional plant-based medicines (Chen, May, Zhou, Zhang, & Xue, 2016) , placing natural products as a potential source to alternative therapy to minimize chemotherapy side effects.
The genus Bauhinia is consisted of about 300 species, spread around tropical countries, and is a promising source of bioactive secondary metabolites, mainly flavonoids. The Bauhinia forficata Link, commonly known as "paw-of-cow," is widely used in Brazilian folk medicine (Cechinel-Filho, 2009 ). Different secondary metabolites have been found in B. forficata preparations, including flavonoids, phenolic acids, and tannins. However, the flavonoids, such as kaempferitrin, kaempferol, and quercetin, are the compounds that occur in major concentration in B. forficata preparations, furnishing to this plant strong antioxidant property (Miceli et al., 2016) . Indeed, B. forficata has displayed diversified pharmacological effects such as antioxidant, antidiabetic (Farag, Sakna, El-Fiky, Shabana, & Wessjohann, 2015) , antimutagenic (Düsman et al., 2013) , hepatoprotector (Salgueiro et al., 2016) , and diuretic (De Souza et al., 2017) .
Considering that the intestinal toxicity is a serious side effect of chemotherapy that may compromise cancer treatment and that flavonoids are known and proven as potent antioxidant and antiinflammatory compounds, it is possible that B. forficata flavonoid-rich fraction may prevent and alleviate intestinal mucositis. Therefore, the present study investigated the effects of the flavonoid-rich fraction of leaves from B. forficata (FRF-BF) against intestinal toxicity of irinotecan in intestinal epithelial cells (IEC-6 cells) and in mice.
| MATERIAL AND METHODS

| Chemicals
Irinotecan (CPT-11, from Pfizer, Itapevi, Brazil), loperamide (from Janssen, Sao José dos Campos, Brazil); 3,3′,3,5′-tetramethylbenzidine, The content of total phenols was determined using the FolinCiocalteau reagent according to the method described by Arnous, Makris, and Kefalas (2001) . A detailed description is provided in Boeing et al. (2016) . The total polyphenol concentration was calculated using tannic acid curve as a standard. Results were expressed as tannic acid equivalents in mg for total phenolic content.
Key Points
• FRF-BF and kaempferitrin prevent the irinotecaninduced cytotoxicity in IEC-6 cells.
• FRF-BF decreases the intestinal motility in health mice.
• Irinotecan promotes the destruction of the Brunner gland region in the duodenal submucous of mice.
• FRF-BF attenuates the intestinal toxicity induced by irinotecan at least in part by its antioxidant potential.
• FRF-BF does not interfere in antitumor action of irinotecan and exerts per se antitumoral activity in mice.
| Kaempferitrin quantification
A calibration curve was made with different concentrations of kaempferitrin in order to measure its content in the FRF-BF. A methanol kaempferitrin stock solution (100 μg/ml) was diluted in the same solvent to obtain standard solutions at the concentration of 5 to 100 μg/ml of kaempferitrin. Concentration versus area graphs curve was constructed, and the respective correlation coefficients (r White/Abs. Vehicle × 100.
| Irinotecan-induced cytotoxicity on IEC-6 cells
The IEC-6 cells (1 × 10 5 /well) were incubated concomitantly with irinotecan (30 or 100 μM) plus FRF-BF (10, 30, or 100 μg/ml) during 24 hr. After this period, MTT assay was performed to verify the cell viability, as described in Section 2.4.1.
To verify the chemopreventive effects of FRF-BF or kaempferitrin against cytotoxicity induced by irinotecan, IEC-6 cells were seeded, plated (1 × 10 5 ), and incubated with FRF-BF or kaempferitrin at different concentrations (10, 30, and 100 μg/ml). After 24 hr, the cells were exposed to irinotecan (30 or 100 μM). After 24 hr, MTT assay was performed to verify the cell viability, as described in Section 2.4.1.
| Animals
Swiss mice (25-35 g) and C57BL/6 mice (20-25 g) from Central
Vivarium 
| Measurement of intestinal motility in mice
Fasted male Swiss mice were randomly divided and orally treated with vehicle (water, 10 ml/kg, n = 6), loperamide (10 mg/kg, n = 6), or FRF-BF (30, 100, and 300 mg/kg, n = 6 for each group) 30 min prior to administration of 0.8 ml of a semisolid marker solution (0.05% phenol red plus 1.5% carboxymethyl cellulose). After 20 min, the mice were euthanized, and small intestine was dissected out from the pylorus to the ileocecal junction to measure intestinal motility as described by Reynell and Spray (1958) , with a few modifications. The total length of the small intestine and the distance covered by phenol red solution were then measured. Intestinal transit was expressed in percentage as calculated from IT = X/Y × 100, where X is distance traveled by phenol red and Y is total length of the small intestine.
| Irinotecan-induced intestinal mucositis
The mice were randomly divided into different groups (n = 6) and orally treated with vehicle (water, 10 ml/kg), loperamide (10 mg/kg), 
| Diarrhea score
The diarrhea is a crucial parameter of the intestinal mucositis installation in mice, as well as in the clinical practice. As proposed by Kurita et al. (2000) , scores were assigned to measure this parameter, as follows: 0 = normal appearance of stools, 1 = slightly altered stool, slightly moist, 2 = wet feces with little perianal dirt, and 3 = wet feces quite perianal dirt.
| Histological and histochemical analysis
The duodenal and colonic fixed segments were processed employing standard histological procedures and stained using hematoxylin-eosin method to examination ion light microscopy under magnification of 100× to evaluate the histopathological chances induced in this tissue after irinotecan exposure.
Besides, the thickness of the muscular tunica was measured under magnification of 40×. Sixty-six measurements of each structure were Histochemical analyses were performed to evaluate the integrity of the mucin layer and goblet cells in the duodenum, according to Umegaki, Yoda, Tokioka, Murano, and Higuchi (2010) . A part of histological slices were stained by the periodic acid of Schiff (PAS) technique for the analysis of the amount of neutral mucin. Another part of the slices were stained by Alcian Blue (pH 2.5) method for analysis of goblet cell and acid mucin according to Myers et al. (2008) . A total of 2,500 epithelial cells were counted in the mucous tunica of each sample, as well as goblet cells found between these cells. From the number of goblet cells in this range, the ratio of goblet cells/100 epithelial cells was calculated.
| Preparation of the intestinal subcellular fraction
Duodenal and colon samples were homogenized with 200-mM potassium phosphate buffer (pH 6.5) and used to measure the reduced glutathione (GSH) and tumor necrosis factor-alpha (TNF-α). After that, the homogenate was centrifuged at 4,000 rpm for 20 min at 4°C, and myeloperoxidase (MPO) activity was measured in the precipitate.
| Quantification of the GSH levels
Aliquots of 50 μg of tissue homogenate were mixed with 12% trichloroacetic acid was centrifuged (4,000 rpm, 15 min at 4°C), as described by Sedlak and Lindsay (1968) . The absorbance of supernatant plus TRIS buffer (0.4 M, pH 8.9) and 0.01 M 5,5′-dithiobis 2-nitrobenzoic acid was measured at 420 nm. The values were interpolated to a standard curve of GSH (1-10 mg/ml) and expressed as mg GSH/g of tissue.
| Determination of TNF-α
The TNF-α amount from the duodenum and colon were analyzed according to the manufacturer's instructions, using ELISA kit from BD Biosciences (Franklin Lakes, NJ). Absorbance was measured at 450 and 550 nm, and the results were expressed as pg/ml.
| MPO activity
The MPO activity was performed as described by Bradley et al. (1982) and modified by Young, Kheifets, Ballaron, and Young (1989) . Briefly, precipitate prepared as described above was suspended in 0.5% hexadecyltrimethylammonium bromide and centrifuged at 12,000 rpm, for 20 min at 4°C. The MPO activity in the supernatant was determined at 620 nm in the presence of 50-mM H 2 O 2 and
18.4-mM 3,3′,3,5′-tetramethylbenzidine and expressed as units of mili-optic density (mOD)/mg of protein/3 min.
| Evaluation of bacterial translocation
Spleen and liver samples from mice exposed to irinotecan were collected aseptically, and a fragment (~100 mg) was plated in 24-well plates with sterile phosphate buffer saline. To the microbiological examination, the fragments were homogenized and seeded in
McConkey Agar and Blood Agar cultures. Then, samples were incubated at 37°C and examined after 24 hr, 48 hr, and 7 days (Alencar et al., 2002) .
| Murine melanoma induction
To induced melanoma, 2 × 10 5 B16F10 melanoma cells were injected subcutaneous on the right flank of the animals, as described by Arifa et al. (2016) . The animals were divided into the following groups (n = 6): vehicle, vehicle plus irinotecan, FRF-BF plus irinotecan, and FRF-BF. The treatments started 15 days after tumor induction, administered once a day, by 6 days. The administration of vehicle (water, 10 ml/kg) or FRF-BF (100 mg/kg) was orally, whereas the irinotecan (75 mg/kg) were administered by intraperitoneal route. The tumor area (mm 2 ) was measured once a day using a digital caliper. After the end of the treatment period, mice were euthanized in CO 2 atmosphere; the tumors were excised and weighed. Then, the volume (mm 3 ) of each tumor was measured using a digital caliper.
| Statistical analysis
For parametric data have been used the t-test or one-or two-way analysis of variance (ANOVA) followed by Bonferroni post-test. The results have been expressed as mean ± S.E.M. The nonparametric results were expressed as median ± interquartile range and analyzed by the Kruskal-Wallis test followed by Dunn's test. In all cases, a p < 0.05 was considered significant, and the GraphPad Prism version 5.00 for Windows (GraphPad Software, California, USA) was employed.
3 | RESULTS
| Total phenolic and kaempferitrin content in FRF-BF
The amount of phenolic content of the FRF-BF is shown in Table 1 . An analytical curve was obtained using a series of solutions of the kaempferitrin (5-100 μg/ml), and the equation of the line was calcu- curve was applied and the amount of kaempferitrin determined as 40.2 mg/g in the FRF-BF. The experiments were done in triplicate.
| FRF-BF and kaempferitrin protect IEC-6 cells against irinotecan-induced cytotoxicity
The incubation of IEC-6 cells with FRF-BF (1-30 μg/ml, Figure 1a ) or kaempferitrin (1μ30 μg/ml, Figure 1b ) did not reduce cellular viability.
In contrast, irinotecan incubation at the concentrations of 10, 30, and 100 μM reduced the IEC-6 cells viability by 24%, 28%, and 23%, respectively ( Figure 2a ). As shown in Figure 2b and 2c, the incubation at the same time of FRF-BF (10, 30, and 100 μg/ml) and irinotecan not avoided the cytotoxicity induced by this drug at concentrations of the 30 or 100 μM, respectively. Interestingly, the pretreatment by 24 hr with FRF-BF (10, 30, and 100 μg/ml, Figure 3a and 3b) or kaempferitrin (10, 30, and 100 μg/ml, Figure 3c and 3d) prevented the decrease in cell viability promoted by irinotecan. The experiments were done in triplicate.
| FRF-BF reduces intestinal motility in mice
As shown in Figure 4 , the oral treatment with FRF-BF at doses of 100
and 300 mg/kg reduced the intestinal transit by 25.57% and 27.11%, respectively, relative to vehicle group (45.64 ± 2.35% of intestinal FIGURE 1 Effects of flavonoid-rich fraction of leaves from Bauhinia forficata (FRF-BF) and kaempferitrin on the cell viability of intestinal cells. IEC cells were treated with vehicle (phosphate-buffered saline, Basal group), DMSO (30%), FRF-BF (1-30 μg/ml, a), or kaempferitrin (1-30 μg/ml, b). After incubation for 24 hr, MTT assay was performed. The data are reported as means ± Standard Error of the mean (SEM). ***p < 0.001 versus Basal group. One-way analysis of variance followed by Bonferroni test. The experiments were done in triplicate FIGURE 2 Effects of the concomitant incubation of flavonoid-rich fraction of leaves from Bauhinia forficata (FRF-BF) against cytotoxicity induced by irinotecan. IEC-6 cells were treated with vehicle (phosphate-buffered saline, Basal group), DMSO (30%), irinotecan (10-100 μM, a), FRF-BF (1-30 μg/ml) plus 30-μM irinotecan (b), or FRF-BF (1-30 μg/ml) plus 100-μM irinotecan (c). After incubation for 24 hr, MTT assay was performed. The data are reported as means ± SEM. ***p < 0.001 versus Basal group. One-way analysis of variance followed by Bonferroni test. The experiments were done in triplicate transit rate). As expected, loperamide (10 mg/kg, the positive control) also reduced the intestinal transit.
| FRF-BF reduces signs of irinotecan-induced intestinal mucositis in mice
The minimum effective dose of FRF-BF to reduce intestinal transit rate was chosen to evaluate its action against irinotecan-induced mucositis. The FRF-BR administration (100 mg/kg, p.o, once a day by 14 days) have not been able avoid the weight loss caused by irinotecan administration ( Figure Figure 5a ), however, have attenuated diarrhea induced by F5 irinotecan ( Figure Figure 5b ), when compared with vehicle group. In contrast, loperamide was not able to reduce the diarrhea induced by irinotecan. The weight loss of each animal was evaluated daily, but no difference was found between the experimental groups exposed to irinotecan.
As expected, the duodenum and colon dry weight were decreased by 29% and 18%, respectively, in mice treated with vehicle and irinotecan, compared with naive group (1.13 ± 0.06 g and 1,07 ± 0.05 g, respectively, Table 2 ). In contrary, the treatment with FRF-BF (100 mg/ kg) avoided the decrease in duodenum and colon dry weight induced by irinotecan (Table 2 ). The wet to dry weight ratio of duodenum was analyzed as an indirect edema indicator, showing an increase of 80% in this parameter in mice treated with vehicle and exposed to irinotecan; however, FRF-BF (100 mg/kg) avoided it (Table 2) .
3.5 | FRF-BF avoided the decrease in the weight of liver, but not of the spleen, of mice exposed to irinotecan
The spleen weight from mice treated with FRF-BF (100 mg/kg), loperamide (10 mg/kg), or vehicle was reduced by 70.31%, 78.7%, and 76.33%, respectively, when compared with naive group FIGURE 3 Chemopreventive effects of flavonoid-rich fraction of leaves from Bauhinia forficata (FRF-BF) or kaempferitrin against cytotoxicity induced by irinotecan. IEC-6 cells were treated with vehicle (phosphate-buffered saline, Basal group), DMSO (30%), FRF-BF (10-100 μg/ml, a and b), or kaempferitrin (10-100 μg/ml, c and d). After 24 hr, cells were incubated with 30 or 100 μM of irinotecan, and MTT assay was performed 24 hr after. The data are reported as means ± SEM. ***p < 0.001 versus Basal group. One-way analysis of variance followed by Bonferroni test. The experiments were done in triplicate FIGURE 4 Effects of flavonoid-rich fraction of leaves from Bauhinia forficata (FRF-BF) on intestinal motility of mice. Animals were orally treated with vehicle (VEH: water, 10 ml/kg), loperamide (Lop: 10 mg/kg), or FRF-BF (30-300 mg/kg). The data are reported as means ± SEM (n = 6). **p < 0.01 and *p < 0.05 versus vehicle group. One-way analysis of variance followed by Bonferroni test (0.87 ± 0.20, Table 2 ). Besides, the liver weight in mice treated with FRF-BF did not present decrease when compared to the naive group (5.91 ± 0.28 g, Table 2 ).
3.6 | FRF-BF reduces histological damage induced by irinotecan in duodenum and colon of mice As depicted in Figure 8a , the number of goblet cells/field in the duodenum stained by Acian blue was increased in the groups treated with vehicle and loperamide (10 mg/kg). Interestingly, the FRF-BF group presented no significant difference when compared with naive (p > 0.05). No changes were verified in the number of goblet cells/field FIGURE 5 Effects of FRF-BF on (a) weight loss and (b) diarrhea score in irinotecan-induced intestinal mucositis in mice. Animals were treated by 13 days with vehicle (VEH: water, 10 ml/kg, p.o), loperamide (10 mg/kg), or FRF-BF (100 mg/kg, p.o). Seven days after the first oral administration, the animals received irinotecan (75 mg/kg, i.p) once a day by 5 days. Naive group received saline (10 ml/kg, i.p) instead of irinotecan. a: two-way analysis of variance followed by Bonferroni test, data are reported as means ± SEM (n = 6 in the colon stained by Acian blue (Figure 8b ). Moreover, representative images for these analyses are depicted in Figure 9 .
Additionally, it was observed that irinotecan administration decreased by 8.69% the PAS-stained cells, when compared with naive group (5.06 ± 0.31), whereas the oral treatment with FRF-BF (100 mg/kg) maintained this parameters in similar values to naive group (p > 0.05, Figure 10a ). In the colon, there was no significant difference between the analyzed groups in both histochemical techniques ( Figure 10b ). Representative images for these analyses are depicted in Figure 11 .
In relation to the measurement of muscle tunica height in duodenum ( Figure 12a ) and colon (Figure 12a) , irinotecan administration induced a significant decrease in thickness in both segments in animals treated with vehicle. FRF-BF administration reduced partially this decrease in colon, but not in duodenum, when compared with the naive control group.
3.7 | FRF-BF increases the GSH viability, reduces the MPO activity, and decreases the TNF-α amount in intestine segments of mice exposed to irinotecan
The GSH levels in the duodenum and colon of mice treated with vehicle and exposed to irinotecan reach a mean of 111.1 ± 23.8
( Figure 13a ) and 46.3 ± 4.8 μg/mg of tissue (Figure 13b ), respectively. The treatment with FRF-BF (100 mg/kg) increased these levels by 243% in duodenum and by 149% in colon, compared with mice treated with vehicle. Moreover, the FRF-BF (100 mg/kg) administration reduced the MPO activity in the duodenum, but not in colon, by 32.48%, compared with vehicle group exposed to irinotecan (54.2 ± 8.0 mOD/mg of protein). In the measurements of TNF-α, the FRF-BF (100 mg/kg) administration decreased by 34% the levels of this inflammatory parameter in the duodenum, but not in colon, of mice exposed to irinotecan (434.3 ± 96.7 pg/ml, Table 3 ).
| Bacterial translocation evaluation
Concerning the bacterial translocation, we checked the samples of liver and spleen tissues of all experimental groups, but no bacterial translocation was found in these samples.
| FRF-BF attenuates irinotecan-induced intestinal mucositis without interfering in its antitumor activity
The The chemopreventive activity of FRF-BF and kaempferitrin against irinotecan-induced cytotoxicity in IEC-6 cells was confirmed.
The irinotecan-induced cytotoxicity in IEC-6 cells was avoided after It is important to note that infusions of leaves of B. forficata are popularly used for medicinal purposes in Brazil. As pointed out by Pinheiro, Johansson, Pizzolatti, and Biavatti (2006) , kaempferitrin was found in aqueous and hydroalcoholic extracts from B. forficata leaves collected in Itajaí/SC (Brazil). However, the amount of this compound was found at least three times less in aqueous preparation compared with hydroalcoholic extracts. In view of this, is possible suggest that infusion from B. forficata can be beneficial effects to treat mucositis, but likely would be necessary a greater ingestion of infusion when compared with extracts or semi-purified fractions which possess high kaempferitrin content.
Extending the in vitro findings, in vivo experiment revealed the inhibitory capability of FRF-BF on the intestinal transit rate at 100 and 300 mg/kg by oral route. Thus, the hypothesis about the beneficial effects of FRF-BF in the intestinal mucositis was straightened, and the minimum effective dose in this trial was employed in the sequential experiments of this research. Among phytochemical compounds, flavonoids and tannins are the main substances reported as preventing diarrhea. Flavonoids reduce intestinal motility, water, and electrolyte secretion, beyond their antioxidant potential, and can act suppressing catalytic activities of different enzymes involved in prostaglandin synthesis (Birru, Asrie, Adinew, & Tsegaw, 2016) . In this way, probably the flavonoids amount in FRF-BF can exerts pivotal role in its inhibitory effects on intestinal transit rate.
The patients have varying degrees of malnutrition due to cancer pathology, and the side effects of chemotherapy aggravate their malnutrition, which leads to decrease in the body weight and increase the patients suffering (Wang et al., 2017) . Besides, the diarrhea observed in patients receiving chemotherapy has a crucial role in this process (Soares et al., 2008) . Although B. forficata has a popular indication for combating diarrhea (Mishra, Seth, & Maurya, 2016) , there is a lack of scientific evidence of its efficacy in this field.
The treatment with FRF-BF reduced the diarrhea degree, but did not avoid the loss on the body weight provoked by irinotecan, when compared with negative control. In addition, the results achieved in
FIGURE 12
Effects of FRF-BF on the muscle tunica height in the (a) duodenum and (b) colon from mice exposed to irinotecan-induced intestinal mucositis. Lop: loperamide (10 mg/kg, p.o); FRF-BF (100 mg/kg, p.o). One-way analysis of variance followed by Bonferroni test, data are reported as means ± SEM (n = 6). # p < 0.05 and ### p < 0.001 versus naive group. *p < 0.05 and **p < 0.01 versus vehicle group (VEH, water, 10 ml/kg, p.o) FIGURE 13 Effects of flavonoid-rich fraction of leaves from Bauhinia forficata (FRF-BF) on the gluthatione reduced (GSH) levels in (a) duodenum and (b) colon from mice exposed to irinotecan-induced intestinal mucositis. Lop: loperamide (10 mg/kg, p.o); FRF-BF (100 mg/kg, p.o). One-way analysis of ariance followed by Bonferroni test, data are reported as means ± SEM (n = 6).
## p < 0.01 versus naive group. **p < 0.01 versus vehicle group (VEH, water, 10 ml/kg, p.o) mice treated with loperamide reflect the limitations on the clinical practice. Thus, considering the lack of effectiveness of loperamide in reducing the irinotecan-induced diarrhea, it is possible to infer that an opioid antagonist is not involved in the antidiarrheal action elicited by FRF-BF. Besides, this effect can be associated with the amount of flavonoids present in its composition, especially to kaempferitrin, which displays antioxidant and anti-inflammatory activity (Silva et al., 2000) . Fang, Rao, and Tzeng (2005) described the capability of kaempferitrin to reduce the production of nitric oxide (NO) and inflammatory cytokines (TNF-α and IL-12) in a dose-dependent manner in macrophages stimulated with lipopolysaccharide plus interferon gamma. It is known that enterocytes can produce NO under inflammatory conditions (Forsythe, Xu, Lu, & Deitch, 2002) and that it favors the dysregulation of intestinal motility (Natarajan, Abraham, Kota, & Selvakumar, 2017) ; moreover, cytokines involved in intestinal inflammation may be correlated positively with mucositis-induced diarrhea (Meirovitz et al., 2010) . In view of these and based in the findings described by Fang et al. (2005) , it is probably that the anti-inflammatory properties of flavonoids from FRF-BF, mainly kaempferitrin, can ensure the reduction in diarrhea induced by irinotecan.
Organ weights are commonly used to evaluate toxicity, because changes in these parameters are related to alteration in their functioning (Sellers et al., 2007) . Thus, chemotherapy toxicity in organs not affected by cancer is one of its limitations (Aikemu et al., 2016) . As found in the literature, all mice treated with irinotecan showed reduction in spleen weight (Bajic et al., 2016; Cheah, Howarth, & Bastian, 2014) , which can be justified by the chemotherapeutic-induced immunosuppression.
Up to date, hepatotoxic side effects during chemotherapy have also been a clinical challenge in the oncology (Thatishetty, Agresti, & O'Brien, 2013) . In fact, animals receiving vehicle and exposed to irinotecan showed a reduced liver weight, whereas the treatment with FRF-BF avoided it. Similar results were achieved by Aikemu et al. (2016) , which described the preventive potential of a traditional herbal preparation rich in flavonoids in the reduction of liver weight promoted by 5-fluorouracil and doxorubicin in mice. However, it is relevant to point out that the liver weight is not a gold standard for assessing hepatotoxicity, but the hepatoprotective properties of B. forficata tea and kaempferitrin were already described by Salgueiro et al. (2016) and by Nguyen et al. (2017) , respectively, reinforcing the hypothesis that FRF-BF can exert hepatoprotective actions against irinotecan.
Due to the fact that small intestine crypt cells are more sensitive to the toxicity and apoptosis exerted by irinotecan (Ribeiro et al., 2016) , changes in the weight of the duodenum, but not of the colon, were observed. In contrary, FRF-BF protected the duodenum, avoiding the tissue loss and edema in this intestinal segment.
Besides, the treatment with FRF-BF also elicited the qualitative improvement in the histological architecture of the duodenum of mice exposed to irinotecan. It was possible to observe the partial preservation of the goblet cells, as well as the mucus layer. In contrast, animals receiving irinotecan and treated with vehicle showed evident histological damage with intense ulceration and reduction of villi height.
The pathobiology of alimentary mucositis is complex, and major progress has been made in recent years in understanding the mechanisms of irinotecan-induced small intestinal mucositis, which appears to be more prominent than colonic damage. As described by Logan et al. (2008) , irinotecan affects different sites of gastrointestinal mucosa in different manners. Those authors described histological and immunohistochemical evidence of changes occurring concurrently in different sites of the alimentary tract following irinotecan administration in rats, providing results about the differential role of NF-kappaB and associated proinflammatory cytokines in the pathobiology of the mucositis. In view of this, it is possible to infer that the differential effects of FRF-BF in the duodenum and colon are due to differences in the pathophysiological mechanisms resulting from the action of irinotecan in these tissues. Thus, a varied damage promotes a varied response of the preparations from B. forficata tested in the study.
The Brunner's glands are located in the submucosa of the duodenum, secreting an alkaline fluid containing mucin to protect the mucosa from the acidic stomach contents entering the duodenum (Sedano, Swamy, Jain, & Gupta, 2015) . Unprecedentedly, the histological observation of slices from duodenum of mice exposed to irinotecan showed a severe depletion of the Brunner's glands. This destruction leads to an unprotected enterocyte exposure to chime acidity, further accentuating the severity of the damage associated with irinotecan therapy. In agreement to this pathological finding, the histochemical analysis revealed a decreased level of neutral mucin (PAS staining) in parallel to an increased secretion of acid mucin (Alcian Blue staining) after the irinotecan treatment. Goblet cells are highly polarized exocrine cells that synthesize and secrete mucins (Robbe, Capon, Coddeville, & Michalski, 2004; Specian & Oliver, 1991) . Preclinical studies have been demonstrated increases in mucin secretion (Bowen et al., 2007; Gibson, Bowen, Inglis, Cummins, & Keefe, 2003) , which together with reduced intestinal absorption of fluids lead to the late secretory diarrhea evoked by irinotecan therapy.
In contrast to depletion of Brunner's glands, an increased number of Goblet cells Alcian Blue positive was found in mice exposed to irinotecan, confirming increasing acid mucin secretion. This increase correlates with the incidence of diarrhea, given that the attenuation of this clinical sign in mice treated with FRF-BF was related to the preservation of the Brunner's glands and the normalization in the Goblet cells stained by Alcian Blue method.
The improvement in clinical signals and intestinal injury after FRF-BF treatment was associated with improvement in the availability of the GSH, a crucial endogen antioxidant in the cellular defense against oxidative stress (Nemmiche, 2017) . The oxidative stress has been demonstrated to exert a fundamental role in mucositis induced by irinotecan (Rtibi et al., 2017) and the production of reactive oxygen species (ROS) from enterocytes exposed to chemotherapy corroborates in this process (Arifa et al., 2016) . Several studies have demonstrated that flavonoids act favoring the antioxidant defenses (Goya et al., 2016; Pérez-Cano & Castell, 2016) . Indeed, the increase in the concentrations of GSH exerted by B. forficata was previously described by Damasceno and Rudge (2001) in diabetic pregnant rats in hepatic tissue.
A continuous supply of antioxidant molecules is necessary for ROS inactivation, and the augmented viability of GSH promoted by FRF-BF can prevent or diminish ROS-induced damage in intestine. In an attempt to ROS production during irinotecan-induced mucositis, Ribeiro et al. (2016) evidenced the neutrophil accumulation as a pivotal source of ROS, especially in the small intestine. As an indirect measure of neutrophil migration, the FRF-BF treatment was able to reduce MPO activity in duodenum tissue, indicating its anti-inflammatory effect. As stated by Shi et al. (2016) , both cancer and chemotherapy cause increased release of proinflammatory cytokines, especially TNF-α. The anti-inflammatory potential of FRF-BF was accompanied by reduced amount of TNF-α in the duodenum. It is relevant to infer the contribution of the kaempferitrin in the anti-inflammatory effects displayed by FRF-BF, due to its inhibitory capability on MPO activity (Regasini et al., 2008) and the inhibitory effect on the production of NO from macrophages (Fang et al., 2005) .
Because we observed an attenuation of mucositis after FRF-BF treatment, it is important to emphasize that this protective effect does and irinotecan was not observed and these data need to be carefully interpreted because to evaluate synergistic effects, it is prudent to test more than one dose of each sample tested. Despite this, to date and to the knowledge of the authors, this was the first work that demonstrated the in vivo antitumor effect of this specie, placing preparation of B. forficata in a prominent place, as a source of suitable phytochemicals for the prevention of intestinal side effects linked to antineoplastic therapy and for the fight against cancer.
In conclusion, our data confirmed the protective action of FRF-BF against irinotecan-induced mucositis by the maintenance of protective factors in the duodenum, including the Brunnet's gland preservation, the normalized mucin secretion, and the increased viability of endogen antioxidants (mainly GSH). In parallel, the inflammatory process at the duodenum was attenuated by FRF-BF administration. B. forficata appears to be a promising alternative therapy to the management of chemotherapy induced mucositis, without interfering in the antitumor effect of the chemotherapeutic drug and still being able to promote antitumor effect.
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